PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1564079
PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1564079
Cancer Gene Therapy
Global Cancer Gene Therapy Market to Reach US$8.8 Billion by 2030
The global market for Cancer Gene Therapy estimated at US$2.3 Billion in the year 2023, is expected to reach US$8.8 Billion by 2030, growing at a CAGR of 21.1% over the analysis period 2023-2030. Oncolytic Virotherapy, one of the segments analyzed in the report, is expected to record a 21.9% CAGR and reach US$4.3 Billion by the end of the analysis period. Growth in the Gene Transfer Therapy segment is estimated at 15.7% CAGR over the analysis period.
The U.S. Market is Estimated at US$615.4 Million While China is Forecast to Grow at 20.0% CAGR
The Cancer Gene Therapy market in the U.S. is estimated at US$615.4 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$1.3 Billion by the year 2030 trailing a CAGR of 20.0% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 19.0% and 17.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 14.0% CAGR.
Global Cancer Gene Therapy Market - Key Trends and Drivers Summarized
Why Is Cancer Gene Therapy Revolutionizing Cancer Treatment?
Cancer gene therapy represents a groundbreaking approach in the fight against cancer, offering innovative solutions by targeting the genetic root causes of cancer rather than just treating the symptoms. Unlike traditional treatments like chemotherapy and radiation, which attack both healthy and cancerous cells, gene therapy aims to alter or repair the genes that cause cancer to develop and spread. This method provides a more precise and potentially less harmful alternative. Techniques such as gene editing, using CRISPR technology, or delivering therapeutic genes via viral vectors, allow doctors to replace mutated genes, introduce new genes that help fight cancer, or make cancer cells more recognizable to the immune system. The impact of cancer gene therapy extends beyond treatment, as it offers long-term remission and, in some cases, even a cure. The ability to manipulate the genetic foundation of cancer represents a monumental shift in how we approach treatment, transforming cancer care from a one-size-fits-all model to a more personalized and effective strategy.
How Are Technological Advances Shaping Cancer Gene Therapy?
Technological innovation is the driving force behind the rapid advancements in cancer gene therapy. The most significant development in recent years is the rise of CRISPR-Cas9, a gene-editing technology that allows scientists to precisely modify genes within cancer cells. This tool has revolutionized the field, enabling researchers to either correct mutations or knock out genes that contribute to cancer progression. Viral vectors, which deliver therapeutic genes directly into cancer cells, are also becoming more efficient and safer, thanks to innovations in vector engineering. These vectors are crucial in gene therapy as they provide a way to transport genetic material into cells without causing harm to the patient. Additionally, next-generation sequencing (NGS) is advancing cancer gene therapy by offering deeper insights into the genetic mutations driving individual cancers. This technology allows for highly personalized treatments based on the specific genetic profile of a patient’s cancer. Artificial intelligence and machine learning are also playing pivotal roles by analyzing large datasets and predicting the outcomes of gene therapy interventions, making it easier to design effective treatments. These technological advances have not only made gene therapy more accessible but have also improved its safety and efficacy, driving its growth in the oncology field.
What Are the Emerging Trends and Challenges in Cancer Gene Therapy?
Several key trends are currently shaping the cancer gene therapy market, each contributing to the expansion and refinement of this innovative treatment modality. One of the most prominent trends is the growing focus on personalized medicine. As cancer gene therapy becomes more tailored to individual patients based on their genetic makeup, the industry is seeing a shift towards highly customized treatments that offer better outcomes. Another trend is the increasing use of immunotherapy in combination with gene therapy. By enhancing the immune system's ability to recognize and destroy cancer cells, these therapies are becoming more effective and versatile in treating various cancer types. However, despite these advancements, cancer gene therapy faces several challenges. One significant issue is the high cost of treatment, which can be prohibitive for many patients and healthcare systems. The complexity of developing gene therapies, including regulatory hurdles and long timelines for clinical trials, also poses a challenge to broader market adoption. Additionally, ensuring the safety of gene therapies remains a concern, as there is always a risk of off-target effects or unwanted immune responses. Despite these obstacles, the rapid pace of innovation and growing understanding of cancer genetics continue to drive the development of cancer gene therapies.
What Are the Key Growth Drivers in the Cancer Gene Therapy Market?
The growth in the cancer gene therapy market is driven by several factors, including advances in gene editing technologies, the increasing focus on personalized medicine, and the rising incidence of cancer globally. One of the most significant drivers is the development of tools like CRISPR-Cas9 and other gene-editing technologies, which have greatly enhanced the precision and effectiveness of cancer gene therapy. The push towards personalized medicine is also a major growth factor, as more patients and healthcare providers seek treatments that are tailored to the individual genetic mutations driving a patient’s cancer. This demand for personalized, targeted treatments has led to increased investment in the research and development of gene therapies. Additionally, the rising prevalence of cancer worldwide, particularly in aging populations, is contributing to the growing need for innovative therapies that can offer long-term solutions or even cures. Immunotherapy advancements, where gene therapy is used to modify immune cells to better fight cancer, are further expanding the therapeutic landscape. Regulatory approvals and breakthrough designations for certain gene therapies are accelerating their entry into the market, allowing for faster adoption. As a result, the combination of technological innovation, personalized approaches, and increasing cancer cases continues to fuel the robust growth of the cancer gene therapy market.
Select Competitors (Total 42 Featured) -
- Adaptimmune Therapeutics plc
- Advantagene, Inc.
- Altor Bioscience (a NANT Company)
- Anchiano Therapeutics, Inc.
- bluebird bio, Inc.
- Genelux Corporation
- GlaxoSmithKline PLC
- Merck & Co., Inc.
- OncoGenex Pharmaceuticals, Inc.
- Shanghai Sunway Biotech Co., Ltd.
- Shenzhen SiBiono GeneTech Co., Ltd.
- ZIOPHARM Oncology, Inc.
TABLE OF CONTENTS
I. METHODOLOGY
II. EXECUTIVE SUMMARY
- 1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Cancer Gene Therapy - Global Key Competitors Percentage Market Share in 2024 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
- 2. FOCUS ON SELECT PLAYERS
- 3. MARKET TRENDS & DRIVERS
- Rising Prevalence of Cancer Globally Spurs Growth in Demand for Cancer Gene Therapy
- Advances in Genomic Research Throw the Spotlight on Precision Cancer Gene Therapies
- Focus on Personalized Medicine Expands Addressable Market Opportunity for Gene-Based Cancer Treatments
- Innovations in CRISPR and Gene Editing Propel the Development of Advanced Cancer Gene Therapies
- Growing Investment in Gene Therapy Research Strengthens the Business Case for Novel Cancer Treatments
- Shift Towards Targeted Therapy Accelerates Demand for Gene-Based Cancer Solutions
- Expansion of Immunotherapy Techniques Sustains Growth in the Cancer Gene Therapy Market
- Rising Interest in Oncolytic Virus Therapy Generates New Opportunities for Cancer Gene Therapy
- Increasing Use of Next-Generation Sequencing Drives the Development of Precision Cancer Gene Therapies
- Growing Focus on Rare and Aggressive Cancers Expands Market Potential for Gene Therapy Solutions
- 4. GLOBAL MARKET PERSPECTIVE
- TABLE 1: World Cancer Gene Therapy Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
- TABLE 2: World Recent Past, Current & Future Analysis for Cancer Gene Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
- TABLE 3: World Historic Review for Cancer Gene Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 4: World 16-Year Perspective for Cancer Gene Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
- TABLE 5: World Recent Past, Current & Future Analysis for Oncolytic Virotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
- TABLE 6: World Historic Review for Oncolytic Virotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 7: World 16-Year Perspective for Oncolytic Virotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
- TABLE 8: World Recent Past, Current & Future Analysis for Gene Transfer Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
- TABLE 9: World Historic Review for Gene Transfer Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 10: World 16-Year Perspective for Gene Transfer Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
- TABLE 11: World Recent Past, Current & Future Analysis for Gene-Induced Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
- TABLE 12: World Historic Review for Gene-Induced Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 13: World 16-Year Perspective for Gene-Induced Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
III. MARKET ANALYSIS
- UNITED STATES
- Cancer Gene Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
- TABLE 14: USA Recent Past, Current & Future Analysis for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 15: USA Historic Review for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 16: USA 16-Year Perspective for Cancer Gene Therapy by Segment - Percentage Breakdown of Value Sales for Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy for the Years 2014, 2024 & 2030
- CANADA
- TABLE 17: Canada Recent Past, Current & Future Analysis for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 18: Canada Historic Review for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 19: Canada 16-Year Perspective for Cancer Gene Therapy by Segment - Percentage Breakdown of Value Sales for Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy for the Years 2014, 2024 & 2030
- JAPAN
- Cancer Gene Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
- TABLE 20: Japan Recent Past, Current & Future Analysis for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 21: Japan Historic Review for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 22: Japan 16-Year Perspective for Cancer Gene Therapy by Segment - Percentage Breakdown of Value Sales for Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy for the Years 2014, 2024 & 2030
- CHINA
- Cancer Gene Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
- TABLE 23: China Recent Past, Current & Future Analysis for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 24: China Historic Review for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 25: China 16-Year Perspective for Cancer Gene Therapy by Segment - Percentage Breakdown of Value Sales for Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy for the Years 2014, 2024 & 2030
- EUROPE
- Cancer Gene Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
- TABLE 26: Europe Recent Past, Current & Future Analysis for Cancer Gene Therapy by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
- TABLE 27: Europe Historic Review for Cancer Gene Therapy by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 28: Europe 16-Year Perspective for Cancer Gene Therapy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
- TABLE 29: Europe Recent Past, Current & Future Analysis for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 30: Europe Historic Review for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 31: Europe 16-Year Perspective for Cancer Gene Therapy by Segment - Percentage Breakdown of Value Sales for Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy for the Years 2014, 2024 & 2030
- FRANCE
- Cancer Gene Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
- TABLE 32: France Recent Past, Current & Future Analysis for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 33: France Historic Review for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 34: France 16-Year Perspective for Cancer Gene Therapy by Segment - Percentage Breakdown of Value Sales for Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy for the Years 2014, 2024 & 2030
- GERMANY
- Cancer Gene Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
- TABLE 35: Germany Recent Past, Current & Future Analysis for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 36: Germany Historic Review for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 37: Germany 16-Year Perspective for Cancer Gene Therapy by Segment - Percentage Breakdown of Value Sales for Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy for the Years 2014, 2024 & 2030
- ITALY
- TABLE 38: Italy Recent Past, Current & Future Analysis for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 39: Italy Historic Review for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 40: Italy 16-Year Perspective for Cancer Gene Therapy by Segment - Percentage Breakdown of Value Sales for Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy for the Years 2014, 2024 & 2030
- UNITED KINGDOM
- Cancer Gene Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
- TABLE 41: UK Recent Past, Current & Future Analysis for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 42: UK Historic Review for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 43: UK 16-Year Perspective for Cancer Gene Therapy by Segment - Percentage Breakdown of Value Sales for Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy for the Years 2014, 2024 & 2030
- REST OF EUROPE
- TABLE 44: Rest of Europe Recent Past, Current & Future Analysis for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 45: Rest of Europe Historic Review for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 46: Rest of Europe 16-Year Perspective for Cancer Gene Therapy by Segment - Percentage Breakdown of Value Sales for Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy for the Years 2014, 2024 & 2030
- ASIA-PACIFIC
- Cancer Gene Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
- TABLE 47: Asia-Pacific Recent Past, Current & Future Analysis for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 48: Asia-Pacific Historic Review for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 49: Asia-Pacific 16-Year Perspective for Cancer Gene Therapy by Segment - Percentage Breakdown of Value Sales for Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy for the Years 2014, 2024 & 2030
- REST OF WORLD
- TABLE 50: Rest of World Recent Past, Current & Future Analysis for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 51: Rest of World Historic Review for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 52: Rest of World 16-Year Perspective for Cancer Gene Therapy by Segment - Percentage Breakdown of Value Sales for Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy for the Years 2014, 2024 & 2030
IV. COMPETITION
